Fate Therapeutics Stock (NASDAQ: FATE) stock price, news, charts, stock research, profile.
Open | $4.790 |
Close | $4.540 |
Volume / Avg. | 4.022M / 2.778M |
Day Range | 4.485 - 5.020 |
52 Wk Range | 1.630 - 8.830 |
Market Cap | $516.575M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 23 |
Short Interest | 17.9% |
Days to Cover | 6.7 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Fate Therapeutics (NASDAQ: FATE) through any online brokerage.
Other companies in Fate Therapeutics’s space includes: KalVista Pharma (NASDAQ:KALV), Valneva (NASDAQ:VALN), Celcuity (NASDAQ:CELC), Korro Bio (NASDAQ:KRRO) and Altimmune (NASDAQ:ALT).
The latest price target for Fate Therapeutics (NASDAQ: FATE) was reported by Wedbush on Tuesday, April 23, 2024. The analyst firm set a price target for 7.00 expecting FATE to rise to within 12 months (a possible 54.19% upside). 23 analyst firms have reported ratings in the last year.
The stock price for Fate Therapeutics (NASDAQ: FATE) is $4.54 last updated April 23, 2024 at 4:05 PM EDT.
There are no upcoming dividends for Fate Therapeutics.
Fate Therapeutics’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Fate Therapeutics.
Fate Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.